[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349019-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349019-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","antitumor-activities-of-chimeric-anti-epha2-antibodies-in-xenograft-models-of-breast-pancreatic-and-colorectal-cancers","Antitumor Activities of Chimeric Anti-EphA2 Antibodies in Xenograft Models of Breast, Pancreatic, and Colorectal Cancers","","Erythropoietin-producing hepatocellular receptor A2 (EphA2) drives tumor malignant progression through EphA2 overexpression and noncanonical signaling, which contributes to oncogenic transformation, metabolic reprogramming, therapeutic resistance, and metastasis. Although EphA2-targeting strategies are under clinical evaluation, reported effects have been inadequate. This study generates recombinant class-switched Ea2Mab-7 variants (Ea2Mab-7-mG2a and Ea2Mab-7-hG1) with high affinity and specific recognition of triple-negative breast cancer, pancreatic cancer, and colorectal cancer cells, producing ADCC and CDC-mediated tumor killing and measurable antitumor activity in xenograft models.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/antitumor-activities-of-chimeric-anti-epha2-antibodies-in-xenograft-models-of-breast-pancreatic-and-colorectal-cancers/349019/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/antitumor-activities-of-chimeric-anti-epha2-antibodies-in-xenograft-models-of-breast-pancreatic-and-colorectal-cancers/349019.png","ImageObject",300,407,{"name":42,"@type":43},"Jordan Avery","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What EphA2-related mechanisms support tumor progression in this study?","Question",{"text":63,"@type":64},"EphA2 overexpression and noncanonical signaling promote oncogenic transformation, metabolic reprogramming, treatment resistance, and metastasis, with S897 phosphorylation playing a central role.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were the Ea2Mab-7 variants evaluated for target recognition and immune killing?",{"text":68,"@type":64},"Ea2Mab-7-mG2a and Ea2Mab-7-hG1 were tested for recognition of breast, pancreatic, and colorectal cancer cells, and for eliciting antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).",{"name":70,"@type":61,"acceptedAnswer":71},"What do the xenograft model results indicate about Ea2Mab-7 variants?",{"text":72,"@type":64},"Both monoclonal antibody variants demonstrated measurable antitumor activity in mouse xenograft models of breast, pancreatic, and colorectal cancers, supporting their potential for EphA2-positive cancer treatment.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349019,1790219750,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":109,"preview_page_count":33,"preview_urls":145},1099523882367,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Article  \nAntitumor Activities of Chimeric Anti-EphA2 Antibodies in Xenograft Models of Breast, Pancreatic, and Colorectal Cancers  \nGuanjie Li 1,†, Hiroyuki Suzuki 1, *,†, Tomokazu Ohishi 2, Hiroyuki Satofuka 1, Kenichiro Ishikawa 1, Kai Shimizu 1, Airi Nomura 1, Haruto Araki 1, Naoki Kojo 1, Kaito Suzuki 1, Saori Handa 1, Takuro Nakamura 1, Miyuki Yanaka 1, Tomohiro Tanaka 1, Mika K. Kaneko 1 and Yukinari Kato 1, *  \n1 Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan; [guanjie.li.e3@tohoku.ac.jp](guanjie.li.e3@tohoku.ac.jp) (G.L.); [hiroyuki.satofuka.e1@tohoku.ac.jp](hiroyuki.satofuka.e1@tohoku.ac.jp) (H.S.); [ken.ishikawa.r3@dc.tohoku.ac.jp](ken.ishikawa.r3@dc.tohoku.ac.jp) (K.I.); [shimizu.kai.p1@dc.tohoku.ac.jp](shimizu.kai.p1@dc.tohoku.ac.jp) (K.S.); [nomura.airi.p3@dc.tohoku.ac.jp](nomura.airi.p3@dc.tohoku.ac.jp) (A.N.); [araki.haruto.r8@dc.tohoku.ac.jp](araki.haruto.r8@dc.tohoku.ac.jp) (H.A.); [kojo.naoki.q4@dc.tohoku.ac.jp](kojo.naoki.q4@dc.tohoku.ac.jp) (N.K.); [suzuki.kaito.q1@dc.tohoku.ac.jp](suzuki.kaito.q1@dc.tohoku.ac.jp) (K.S.); [saori.handa.d3@tohoku.ac.jp](saori.handa.d3@tohoku.ac.jp) (S.H.); [takuro.nakamura.a2@tohoku.ac.jp](takuro.nakamura.a2@tohoku.ac.jp) (T.N.); [miyuki.yanaka.c5@tohoku.ac.jp](miyuki.yanaka.c5@tohoku.ac.jp) (M.Y.); [tomohiro.tanaka.b5@tohoku.ac.jp](tomohiro.tanaka.b5@tohoku.ac.jp) (T.T.); [mika.kaneko.d4@tohoku.ac.jp](mika.kaneko.d4@tohoku.ac.jp) (M.K.K.)  \n2 Institute of Microbial Chemistry (BIKAKEN), Laboratory of Oncology, Microbial Chemistry Research Foundation, 3-14-23 Kamiosaki, Shinagawa-ku, Tokyo 141-0021, Japan; [ohishit@bikaken.or.jp](ohishit@bikaken.or.jp)  \n* [Correspondence: hiroyuki.suzuki.b4@tohoku.ac.jp](Correspondence: hiroyuki.suzuki.b4@tohoku.ac.jp) (H.S.); [yukinari.kato.e6@tohoku.ac.jp](yukinari.kato.e6@tohoku.ac.jp) (Y.K.); Tel.: +81-22-717-8207 (Y.K.)  \n† These authors contributed equally to this work.  \nAbstract  \nErythropoietin-producing hepatocellular receptor A2 (EphA2) has emerged as a key mediator that promotes tumor malignant progression. EphA2 overexpression and its noncanonical signaling lead to oncogenic transformation, metabolic reprogramming, resistance to treatments, and metastasis. Therefore, strategies targeting EphA2 have been evaluated in clinical trials. However, the clinical effects were not sufficient. An anti-EphA2 monoclonal antibody (mAb), Ea 2Mab-7 (mouse IgG 1, κ), demonstrated high affinity and specificity among Eph receptors. In this study, we produced recombinant class-switched Ea2Mab-7 variants, including Ea 2Mab-7-mG2a (mouse IgG 2a) and Ea 2Mab-7-hG1 (human IgG 1) . Both Ea2Mab-7-mG2a and Ea2Mab-7-hG1 recognized human triple-negative breast cancer MDA-MB-231, pancreatic cancer MIA PaCa-2, and colorectal cancer HCT-15 inflow cytometry. Furthermore, both Ea2Mab-7-mG2a and Ea2Mab-7-hG1 exerted significant antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity against these tumors. In mouse xenograft models of breast, pancreatic, and colorectal cancers, both mAbs demonstrated antitumor activity. These results indicate the potential of Ea 2Mab-7 variants for the treatment of EphA2-positive cancers.  \nAcademic Editor: Peter J. K. Kuppen  \nReceived: 5 February 2026  \nRevised: 23 March 2026  \nAccepted: 30 March 2026  \nPublished: 2 April 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \nKeywords: monoclonal antibody therapy; EphA2; ADCC; CDC; breast cancer; pancreatic cancer; colorectal cancer  \n1. Introduction  \nThe erythropoietin-producing hepatocellular (Eph) receptor family constitutes the largest subclass of receptor tyrosine kinases (RTKs) [1] and orchestrates essential physiological processes including embryonic patterning, axon guidance, synaptic formation, and vasc","cbCaii8AKu8TvS0g","https://ap.wps.com/l/cbCaii8AKu8TvS0g","pdf",2734098,16,"English","# Abstract\n# Introduction\n## Eph receptor family and EphA2 roles\n## EphA2 signaling mechanisms and therapeutic targeting\n# Keywords","[{\"question\":\"What EphA2-related mechanisms support tumor progression in this study?\",\"answer\":\"EphA2 overexpression and noncanonical signaling promote oncogenic transformation, metabolic reprogramming, treatment resistance, and metastasis, with S897 phosphorylation playing a central role.\"},{\"question\":\"How were the Ea2Mab-7 variants evaluated for target recognition and immune killing?\",\"answer\":\"Ea2Mab-7-mG2a and Ea2Mab-7-hG1 were tested for recognition of breast, pancreatic, and colorectal cancer cells, and for eliciting antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).\"},{\"question\":\"What do the xenograft model results indicate about Ea2Mab-7 variants?\",\"answer\":\"Both monoclonal antibody variants demonstrated measurable antitumor activity in mouse xenograft models of breast, pancreatic, and colorectal cancers, supporting their potential for EphA2-positive cancer treatment.\"}]","Antitumor Activities of Chimeric Anti-EphA2 Antibodies in Xenograft Models of Breast, Pancreatic, and Colorectal Cancers | PDF",1790081224,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/73c678c63828bc718369fc14e725c735.webp",983,1390,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9bf64216a24f2520e30735e577965393.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0cdd18f5c3e79967b8fea2627fd5b474.webp",981,1387,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/29664e4e62d875088375add1186b6078.webp",980,1385]